company background image
H7T1 logo

HUTCHMED (China) DB:H7T1 Stock Report

Last Price

€13.50

Market Cap

€2.5b

7D

-4.9%

1Y

-11.2%

Updated

25 Dec, 2024

Data

Company Financials +

H7T1 Stock Overview

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. More details

H7T1 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

HUTCHMED (China) Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for HUTCHMED (China)
Historical stock prices
Current Share PriceUK£13.50
52 Week HighUK£19.90
52 Week LowUK£11.10
Beta0.74
1 Month Change-17.18%
3 Month Change-12.34%
1 Year Change-11.18%
3 Year Change-55.59%
5 Year Change-38.64%
Change since IPO-41.36%

Recent News & Updates

Recent updates

Shareholder Returns

H7T1DE PharmaceuticalsDE Market
7D-4.9%-1.7%-1.6%
1Y-11.2%-15.8%6.8%

Return vs Industry: H7T1 exceeded the German Pharmaceuticals industry which returned -15.8% over the past year.

Return vs Market: H7T1 underperformed the German Market which returned 6.8% over the past year.

Price Volatility

Is H7T1's price volatile compared to industry and market?
H7T1 volatility
H7T1 Average Weekly Movement6.9%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.6%
10% least volatile stocks in DE Market2.4%

Stable Share Price: H7T1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: H7T1's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20001,970Wei-Guo Suwww.hutch-med.com

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.

HUTCHMED (China) Limited Fundamentals Summary

How do HUTCHMED (China)'s earnings and revenue compare to its market cap?
H7T1 fundamental statistics
Market cap€2.49b
Earnings (TTM)-€40.37m
Revenue (TTM)€587.53m

4.2x

P/S Ratio

-61.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
H7T1 income statement (TTM)
RevenueUS$610.81m
Cost of RevenueUS$658.26m
Gross Profit-US$47.45m
Other Expenses-US$5.48m
Earnings-US$41.97m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.049
Gross Margin-7.77%
Net Profit Margin-6.87%
Debt/Equity Ratio10.9%

How did H7T1 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:45
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

HUTCHMED (China) Limited is covered by 46 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiangqiao TongBOCI Research Ltd.
Linda LuBOCI Research Ltd.
Alec StranahanBofA Global Research